FDA Grants Breakthrough Status to First Viral-Integration MRD Liquid Biopsy in Hepatocellular Carcinoma

TCM Biotech announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device Designation to CatCHimera, a liquid biopsy platform designed to detect minimal residual disease, MRD, in hepatocellular carcinoma, HCC, after curative treatment. The assay introduces a new ctDNA biomarker class by tracking hepatitis B virus, HBV, and host genome integration junctions rather than conventional somatic mutations.

This makes CatCHimera mechanistically distinct from most ctDNA MRD assays currently in development, which typically rely on tumor-specific single nucleotide variants or indels. Instead, the platform uses HBV integration sites, which are unique to each patient’s tumor clones, as tumor-informed biomarkers. The assay combines capture-based next-generation sequencing with ddPCR and does not require mutation calling.

The designation addresses a major unmet need in liver cancer. HCC remains underrepresented in the MRD field, despite being the third leading cause of cancer death worldwide and carrying a recurrence risk of more than 50% within five years after resection. No ctDNA MRD platform had previously pursued FDA Breakthrough Device Designation specifically for liver cancer.

Clinical data published in Hepatology and Cellular and Molecular Gastroenterology and Hepatology, suggest the platform may offer meaningful advantages in recurrence surveillance. Viral-host DNA was detected in 98% of pre-surgical plasma samples, with a detection limit of about 1.5 cm. In the post-operative setting, CatCHimera showed a mean lead time of 158 days over CT for recurrence detection, with a negative predictive value of 92% and a positive predictive value of 71%.

Performance improved further when combined with AFP and PIVKA-II, reaching 95.8% sensitivity and 95.5% specificity. The platform was also reported to be more sensitive than AFP alone for tumors smaller than 5 cm, a clinically important group in which early detection remains challenging.

CatCHimera was developed in collaboration with the group of Academician Pei-Jer Chen at National Taiwan University. TCM Biotech said the technology is protected by patents across multiple regions, including the United States, the European Union, Singapore, and China. Its molecular diagnostics laboratory operates under Taiwan Food and Drug Administration laboratory-developed test accreditation.

The potential clinical relevance is broad. With an estimated 296 million chronic HBV carriers worldwide, the assay could open a more tailored path for MRD monitoring in HBV-related HCC, where conventional mutation-based ctDNA strategies may be less informative.